FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE and PRODUCT COMPLAINT

2,598 reports of this reaction

3.7% of all FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE reports

#5 most reported adverse reaction

Overview

PRODUCT COMPLAINT is the #5 most commonly reported adverse reaction for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 2,598 FDA adverse event reports linking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to PRODUCT COMPLAINT. This represents approximately 3.7% of all 70,190 adverse event reports for this drug.

Patients taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience product complaint should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PRODUCT COMPLAINT2,598 of 70,190 reports

PRODUCT COMPLAINT is moderately reported among FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE users, representing a notable but not dominant share of adverse events.

Other Side Effects of FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

In addition to product complaint, the following adverse reactions have been reported for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:

Other Drugs Associated with PRODUCT COMPLAINT

The following drugs have also been linked to product complaint in FDA adverse event reports:

BELIMUMABCABOTEGRAVIRDOCOSANOLFLUTICASONE FUROATEFLUTICASONE FUROATE AND VILANTEROL TRIFENATATEGLYCERIN, LIDOCAINEPOLYETHYLENE GLYCOL 400, PROPYLENE GLYCOLPOTASSIUM NITRATEPOTASSIUM NITRATE AND SODIUM FLUORIDEPOTASSIUM NITRATE, SODIUM FLUORIDEUMECLIDINIUMUMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Frequently Asked Questions

Does FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE cause PRODUCT COMPLAINT?

PRODUCT COMPLAINT has been reported as an adverse event in 2,598 FDA reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PRODUCT COMPLAINT with FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

PRODUCT COMPLAINT accounts for approximately 3.7% of all adverse event reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it a notable side effect.

What should I do if I experience PRODUCT COMPLAINT while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

If you experience product complaint while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages

FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE Full ProfileAll Drugs Causing PRODUCT COMPLAINTGlaxoSmithKline LLC Drugs
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.